63 results about "Diabetes in pregnancy" patented technology

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

The invention provides a synthetic polypeptide of Formula I′ (SEQ ID NO: 1):

X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13  I

• • or an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Methods for modulating diabetes, impaired glucose tolerance, gestational diabetes and glucose resistance in a mammal, particularly a human. In one embodiment the method comprises administering a gallotannin composition to a mammal in need of the same. The gallotannin composition comprises one or more select hydrolysable gallotannins. In another embodiment the method comprises administering a gallotannin variant composition comprising one ore more select gallotannin variant compounds to the subject. Methods of preventing or treating weight gain in a subject. The method comprises administering the gallotannin composition of the present invention, the gallotannin variant composition of the present invention, or a combination of the gallotannin composition of the present invention and the gallotannin variant composition of the present invention to the subject. The present invention also relates a gallotannin variant compound or a salt thereof, and a pharmaceutical composition comprising such compound or the salt thereof.

The invention relates to methods and compositions for identifying subjects having, or predisposed to having, gestational diabetes, preeclampsia, and gestational hypertension. The methods are applicable to urine and/or blood samples and can be conducted prior to the third trimester of pregnancy.

The present invention relates to protein markers of gestational diabetes mellitus in urine and the use in early diagnosis. In particular, the present invention relates to the use of an identification reagent selected from the following proteins for preparing reagents for early diagnosis of gestational diabetes mellitus: protein NOV homolog, Peroxiredoxin-5 (PRDX-5), Hepatocyte growth factor-like protein (HFGL) and the combination thereof. The protein NOV homolog, the Peroxiredoxin-5 and the Hepatocyte growth factor-like protein and the combination thereof have good clinical application prospects for early diagnosis of gestational diabetes mellitus.

The invention discloses a special medical-purpose emulsion for relieving diabetic symptoms and a preparation method of the special medical-purpose emulsion. Each liter of the emulsion comprises the following components: 45-80 g of a low-glycemic-index carbohydrate composition, 20-60 g of high-quality protein, 20-60 g of vegetable oil, 50-100 g of malt paste, 0.2-1.0 g of compound vitamins, 0.2-1.0 g of compound minerals, 1-12 g of an emulsifier and 1-5 g of a stabilizer. The special medical-purpose emulsion contains controlled-release carbohydrate, and after compounding is finished, the GI value of the final product is 30-55. The ratio of animal protein to vegetable protein is 2.5:1.5, the branched chain amino acid composition and content are high, and insulin release can be promoted. The mass of medium-chain fatty acid accounts for more than 50% of the total fat content, the emulsion has comprehensive and balanced nutrition, and the product system is high in stability. The special medical-purpose formulated emulsion is suitable for people with diabetes and hyperglycemia symptoms, especially for being used by patients with gestational diabetes mellitus as diet replacement or nutritional supplement, is wide in application range and convenient to use, and also has the effects of promoting lactation, optimizing milk and improving milk quality when used after childbirth.

The invention belongs to the field of food production, and particularly relates to an enteral nutrition preparation for women with gestational diabetes, and a preparation technology thereof. The enteral nutrition preparation comprises the following raw materials: marine animal protein or soybean peptide, laminarin, enzymatic hydrolysis powder of turtle meat, olive oil or tea-seed oil. In addition, the enteral nutrition preparation also contains active probiotics, amino acids, a calcium preparation and fruit and vegetable powder, wherein the dosage form of the enteral nutrition preparation is powder or emulsion. The invention simultaneously discloses a preparation method of two dosage forms of the nutrition preparation. Special pharmacological bioactive substances and nutrient function materials are reasonably compounded aiming at the pathological and physical characteristics of the women with gestational diabetes, and special nutrient requirements and metabolism requirements of infants and mothers, so as to enhance the effects of effective components; comprehensive and balanced nutrition is provided for the women with gestational diabetes; the body immune function is enhanced; the pregnancy reaction is reduced; the gestational diabetes are prevented; blood sugar is reduced in an assisting manner; the nutrition and the health of the infants and mothers for the women with gestational diabetes are well ensured.

The invention relates to the field of medical diagnosis, in particular to biomarkers which are screened by metabonomics and are used for identifying and diagnosing gestational diabetes mellitus, and a model which is used for diagnosing whether a gestational individual is diabetes mellitus or not is established according to the biomarkers. The invention provides a biomarker and a diagnostic model for differential diagnosis of gestational diabetes mellitus, which can be applied to early diagnosis or prediction of gestational diabetes mellitus and have important significance in prevention or treatment of gestational diabetes mellitus.

The present invention is focused on an in vitro method for identifying or screening human subjects at risk of suffering from a pregnancy related disease, in particular from gestational diabetes mellitus or preeclampsia, departing from the level of expression or concentration of a series of biomarkers isolated from a minimally-invasive sample such as gingival crevicular fluid (GCF). Moreover, the method of the invention offers high sensitivity and specificity at an early stage of the pregnancy (see the Examples and figures shown below), which means that it is a strong and cost-effective method for the detection of a pregnancy related disease, in particular gestational diabetes mellitus or preeclampsia, at an early stage of the disease thus procuring effective treatment, avoiding significant long-term adverse effects for both mother and baby.

The invention discloses a screening or early diagnosis kit for high-risk pregnant women with gestational diabetes mellitus enormous children. The invention relates to a screening or early diagnosis kit for a high-risk pregnant woman with gestational diabetes mellitus enormous children. The kit is characterized by comprising a reagent for detecting LncRNA AC015961.2 from a serum exosome. The specificity of the LncRNA AC015961.2 derived from the serum exosome on early diagnosis of the gestational diabetic megatherium can reach 87.5%, and the sensitivity of the LncRNA AC015961.2 can reach 75.0%. According to the present invention, the expression level of the LncRNA AC015961.2 in the serum exosome of the pregnant woman suffering from gestational diabetes can be detected, and the kit can be used for the auxiliary early diagnosis of the gestational diabetes mellitus megatherium, such that the support can be provided for the clinical doctor to accurately predict the occurrence risk of the megatherium and timely adopt the more individualized prevention and treatment scheme so as to furthest reduce the adverse gestational outcome.

The present invention relates to methods of typing a female subject as being at risk of developing gestational diabetes, comprising determining a level of expression of Secreted Frizzled-Related Protein 4 (sFRP4). The invention further relates to methods of treating of a subject being at risk of developing, gestational diabetes, comprising typing the subject according to the methods of the invention, and treating the subject with a dietary meal plan and/or physical activity. The invention additionally relates to kit for a pregnant female subject for susceptibility to gestational diabetes, use of a kit according to the invention for typing a female subject as being at risk of developing gestational diabetes, and to an antibody specific to sFRP4 for use in a method for determining a risk of a female subject of developing gestational diabetes.

The invention relates to a formula of a food therapy capable of recuperating gestational diabetes and a preparation method of the formula. The formula comprises haws, Chinese wolfberry root-bark, radix trichosanthis, polished round-grained rice, maize flour and table salt. The preparation method of the formula comprises the following steps: (1) cleaning the Chinese wolfberry root-bark and the radix trichosanthis with clean water, adding water which is 3-5 times of the raw materials, decocting the Chinese wolfberry root-bark, the radix trichosanthis and the water twice, and filtering off liquid medicines; (2) cleaning the polished round-grained rice, shelling the haws, adding the liquid medicines, adding clean water which is one time of the raw materials, and cooking the polished round-grained rice, the shelled haws and the clean water until the rice is boiled out; (3) adding the maize flour, so that the porridge is made into thin paste; and (4) adding the table salt, and uniformly stirring the thin paste and the table salt so as to obtain the food which can be eaten. The formula of the food therapy capable of recuperating gestational diabetes and the preparation method of the formula, disclosed by the invention, are simple and easy to operate, wide in sources of the raw materials, notable in effect, safe, and free from toxic and side effects.

The invention provides a nutritional diet management map creation method and device based on a gestational period. The method comprises the following steps: acquiring target structured data and target unstructured data related to gestational diabetes mellitus; based on the target structured data, determining symptoms of the gestational diabetes mellitus and nutritional diet information having an association relationship with the symptoms, and based on the symptoms and the nutritional diet information, creating a nutritional diet management map ontology in the gestational period; identifying a target entity relationship matched with the symptom and/or the nutritional diet information in the target unstructured data; and carrying out fusion processing on the nutritional diet management map body and the target entity relationship to generate the gestational diabetes mellitus nutritional diet management map. According to the invention, visual and systematic scientific diet guidance can be provided for the pregnant user in a targeted manner, and the acquisition cost of the nutritional diet scheme is reduced, so that the management effect of the nutritional diet in the gestation period is greatly improved.

The invention involves assays, diagnostics, kits, and assay components for determining levels of glycated CD59 in the assessment of gestational diabetes mellitus and/or related disorders and/or conditions. Some kits comprise a capture antibody capable of associating with a capture epitope on CD59, wherein said capture epitope may lack lysine residue number 41 (K41 ). Kits may also comprise a detection antibody capable of associating with a detection epitope on CD59. Such detection epitopes may comprise glycated K41.

The invention discloses probiotic flavored fermented milk without cane sugar and sweetening agent. The probiotic flavored fermented milk comprises the following components in percentage by weight: 4.0-15.0% of fruit juice, 0.001-0.006% of leavening agent and the balance of raw milk, wherein the total weight percentage of the raw milk is 100%. The invention also discloses a preparation method of the probiotic-flavored fermented milk without sucrose and sweetening agent. By adjusting the formula and not additionally adding cane sugar or a sweetening agent, the product is natural in sweetness and free of bitterness, the immune system of children can be effectively adjusted, and the risk of infant eczema and gestational diabetes mellitus is reduced. Meanwhile, a conventional fermented milk production process is optimized, and a low-temperature stirring and mixing method is adopted, so that the energy consumption is effectively reduced, the high-temperature time of the materials is shortened, and excessive propagation of harmful bacteria is avoided.

The invention provides an application of a urine immunoglobulin kappa constant region (IGKC) and a polypeptide fragment of the IGKC, and particularly relates to an application of a urine IGKC protein and a polypeptide fragment of the IGKC protein in preparation of a preparation for monitoring normal pregnancy or gestational diabetes mellitus. Researches prove that compared with a normal childbearing age woman group (normal control), the expression of IGKC and polypeptide fragments thereof in normal pregnancy and gestational diabetes mellitus groups is increased, and the IGKC and polypeptide fragments thereof can be used for monitoring and auxiliary diagnosis of gestational state or gestational diabetes mellitus patients. According to the invention, the advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of a urine sample are exerted, and the urine IGKC protein and the polypeptide fragment thereof are detected by using the urine sample.

The invention belongs to the field of immunodetection, and particularly relates to a double-index immunochromatography kit for detecting adiponectin (Adipo) and sex hormone binding globulin (SHBG). The main component is an immunochromatography test strip, and the immunochromatography test strip is formed by sequentially pasting a sample pad, a binding pad, a nitrocellulose membrane and absorbent paper on a PVC base plate. Adipo antibody-microspheres and SHBG antibody-microspheres are adsorbed on the binding pad, an Adipo antibody is fixed on the nitrocellulose membrane to form a detection line 1 (T1 line), an SHBG antibody is fixed on the nitrocellulose membrane to form a detection line 2 (T2 line), and an anti-IgG antibody is fixed to form a quality control line (C line). The invention also discloses a process for coupling the Adipo antibody and the SHBG antibody with the microspheres. The Adipo/SHBG detection immunochromatography kit is used to determine the Adipo and SHBG concentrations in blood or other body fluids, and is used for early prediction of insulin resistance, type 2 diabetes mellitus and gestational diabetes mellitus occurrence risks.

The invention discloses a preparation method of a sugar-control nutritious meal for middle and advanced pregnancy of gestational diabetes mellitus. The preparation method comprises the steps that a dietary formula comprises a full-day dietary energy and energy supply nutrient distribution rule, a special food material selection rule and a cooking method selection rule, and the full-day dietary energy and energy supply nutrient distribution rule comprises a productivity nutrient energy supply ratio, full-day distribution of energy and productivity nutrients, protein protection and rich dietaryfiber content. According to the invention, through the nutritional meal, the effect of good blood glucose control and the effect of good nutrition support can be achieved; the insulin utilization ratecan be remarkably reduced; the fetal macrosomia occurrence rate, caesarean delivery rate, neonatal hypoglycemia occurrence rate, premature delivery rate and like are obviously superior to those of current clinical situation of gestational diabetes mellitus; and meanwhile, the diet intervention mode is suitable for gestational diabetes mellitus patients at work.